Bristol Myers Squibb (NYSE symbol BMY) is an American pharmaceutical company. BMY or bmy may also refer to: Bloomsbury Publishing, a British publishing house, LSE symbol BMY Bowen McLaughlin York, a defense manufacturer merged to form United Defense Bramley railway station (Hampshire), England, station code BMY Île Ar…
An institutional-grade, numbers-driven thesis on BMY — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 8, 2026, TradersQuant's model rates BMY (BMY) 57/100. BMY is covered in the Unknown sector. The score blends valuation, growth, earnings quality and momentum into a single grade.
On the fundamentals, BMY shows trailing revenue of $48.19B. This page also tracks BMY's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
BMY currently carries a TradersQuant composite score of 57/100, which we read as a neutral-to-watch signal. This is research, not financial advice — always combine it with your own judgement.
TradersQuant generates a 12-month, three-scenario (bull/base/bear) model forecast for BMY. Open the live page for current figures.
TradersQuant publishes a model-based 12-month price prediction for BMY, and every call is logged and graded publicly against the S&P 500. Open the live page for current figures.
We deliberately don't publish 2030 price predictions for BMY — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
BMY does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
